Real-time Estimate
Cboe BZX
08:47:50 15/05/2024 pm IST
|
5-day change
|
1st Jan Change
|
14.01
USD
|
+6.70%
|
|
+3.86%
|
-12.77%
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
596.3
|
746.6
|
623.3
|
-
|
-
|
Enterprise Value (EV)
1 |
596.3
|
468.3
|
623.3
|
623.3
|
623.3
|
P/E ratio
|
-2.84
x
|
-5.28
x
|
-4.33
x
|
-4.02
x
|
-3.53
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
199
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
199
x
|
EV / EBITDA
|
-9.16
x
|
-5.62
x
|
-3.84
x
|
-3.65
x
|
-3.26
x
|
EV / FCF
|
-9.03
x
|
-7.65
x
|
-3.86
x
|
-3.81
x
|
-3.27
x
|
FCF Yield
|
-11.1%
|
-13.1%
|
-25.9%
|
-26.2%
|
-30.6%
|
Price to Book
|
1.7
x
|
2.88
x
|
3.01
x
|
3.15
x
|
3.62
x
|
Nbr of stocks (in thousands)
|
35,644
|
46,516
|
47,475
|
-
|
-
|
Reference price
2 |
16.73
|
16.05
|
13.13
|
13.13
|
13.13
|
Announcement Date
|
17/03/23
|
20/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
3.125
|
EBITDA
1 |
-
|
-65.11
|
-132.9
|
-162.3
|
-170.7
|
-191.3
|
EBIT
1 |
-
|
-65.11
|
-133.3
|
-168.7
|
-199.4
|
-239.9
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-7,677.84%
|
Earnings before Tax (EBT)
1 |
-
|
-159.8
|
-123.6
|
-159.3
|
-191.8
|
-233.2
|
Net income
1 |
-102.4
|
-159.8
|
-123.6
|
-161.1
|
-191.9
|
-233.1
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-7,459.8%
|
EPS
2 |
-30.64
|
-5.890
|
-3.040
|
-3.035
|
-3.267
|
-3.716
|
Free Cash Flow
1 |
-
|
-66
|
-97.53
|
-161.4
|
-163.5
|
-190.7
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-6,101.76%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
28/02/22
|
17/03/23
|
20/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-11.31
|
-12.81
|
-17.89
|
-23.1
|
-28.96
|
-30.08
|
-33.57
|
-39.41
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-11.31
|
-12.81
|
-17.89
|
-23.1
|
-28.96
|
-30.18
|
-33.91
|
-40.29
|
-49.8
|
-43.33
|
-39.82
|
-38.57
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-67.89
|
-53.93
|
-16.8
|
-21.19
|
-26.89
|
-27.9
|
-31.82
|
-36.96
|
-46.83
|
-39.81
|
-37.59
|
-37.05
|
-
|
-
|
Net income
1 |
-67.89
|
-53.93
|
-16.8
|
-21.19
|
-26.89
|
-27.9
|
-31.82
|
-36.96
|
-46.83
|
-39.81
|
-37.59
|
-37.05
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-10.06
|
-2.030
|
-0.4500
|
-0.5600
|
-0.7100
|
-0.7400
|
-0.8100
|
-0.7800
|
-0.9700
|
-0.8033
|
-0.7036
|
-0.6732
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
08/06/22
|
10/08/22
|
10/11/22
|
17/03/23
|
12/05/23
|
14/08/23
|
09/11/23
|
20/03/24
|
09/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
278
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-66
|
-97.5
|
-161
|
-163
|
-191
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-46.4%
|
-63%
|
-70.7%
|
-76%
|
ROA (Net income/ Total Assets)
|
-
|
-71.9%
|
-37.4%
|
-47.2%
|
-51.7%
|
-55.8%
|
Assets
1 |
-
|
222.2
|
330.8
|
341.2
|
371.2
|
417.8
|
Book Value Per Share
2 |
-
|
9.840
|
5.570
|
4.360
|
4.170
|
3.620
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
10.7
|
2
|
6.5
|
6.5
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
208.1%
|
Announcement Date
|
28/02/22
|
17/03/23
|
20/03/24
|
-
|
-
|
-
|
Last Close Price
13.13
USD Average target price
29
USD Spread / Average Target +120.87% Consensus |
1st Jan change
|
Capi.
|
---|
| -12.77% | 623M | | +26.20% | 49.18B | | +0.77% | 42.11B | | +50.13% | 40.37B | | -5.26% | 28.85B | | +13.01% | 26.09B | | -22.19% | 18.71B | | +8.51% | 13.26B | | +31.72% | 12.32B | | +0.14% | 11.99B |
Other Biotechnology & Medical Research
|